Juan Martin-Liberal1,2, Antonio López-Pousa3, Javier Martínez-Trufero4, Javier Martín-Broto5, Ricardo Cubedo6, Javier Lavernia7, Andrés Redondo8, José Antonio López-Martín9, Nùria Mulet-Margalef1,2, Xavier Sanjuan10, Òscar M Tirado11, Xavier Garcia-Del-Muro12,13,14. 1. Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035, Barcelona, Spain. 2. Sarcoma, Melanoma and Genitourinary Tumors Unit, Institut Català d'Oncologia L'Hospitalet, Avda Gran Via Km 2.7, 08907 L'Hospitalet, Barcelona, Spain. 3. Cancer Medicine Department, Hospital de la Santa Creu i Sant Pau, 08026, Barcelona, Spain. 4. Medical Oncology Department, Hospital Universitario Miguel Servet, 50009, Zaragoza, Spain. 5. Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013, Sevilla, Spain. 6. Medical Oncology Department, Hospital Puerta de Hierro, 28222, Madrid, Spain. 7. Medical Oncology Department, Instituto Valenciano de Oncología, 46009, Valencia, Spain. 8. Medical Oncology Department, Hospital Universitario La Paz, 28046, Madrid, Spain. 9. Medical Oncology Department, Hospital 12 de Octubre, 28041, Madrid, Spain. 10. Pathology Department, Bellvitge University Hospital, 08907, Barcelona, Spain. 11. Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), CIBERONC, Universitat de Barcelona, Avda Gran Via Km 2.7, 08907 L'Hospitalet, Barcelona, Spain. 12. Sarcoma, Melanoma and Genitourinary Tumors Unit, Institut Català d'Oncologia L'Hospitalet, Avda Gran Via Km 2.7, 08907 L'Hospitalet, Barcelona, Spain. garciadelmuro@iconcologia.net. 13. Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), CIBERONC, Universitat de Barcelona, Avda Gran Via Km 2.7, 08907 L'Hospitalet, Barcelona, Spain. garciadelmuro@iconcologia.net. 14. Universitat de Barcelona, 08036, Barcelona, Spain. garciadelmuro@iconcologia.net.
Abstract
BACKGROUND: Gemcitabine plus sirolimus enhances apoptosis in vitro and increases anti-tumor efficacy in vivo in soft-tissue sarcoma (STS) models. OBJECTIVE: The objective of this study was to evaluate the activity and toxicity of the combination of gemcitabine plus sirolimus in patients with STS after failure of standard chemotherapy. PATIENTS AND METHODS: Advanced STS patients, previously treated with doxorubicin and/or ifosfamide, were included in this single-arm phase II study. Patients received gemcitabine 800 mg/m2 intravenously (iv) at 10 mg/m2/min on days 1 and 8 every 3 weeks plus sirolimus 5 mg daily orally (po). After enrolment of the first 12 patients, the study protocol was amended due to toxicity and the starting dose of sirolimus was reduced to 3 mg daily po. Archival tumor samples were analyzed for extracellular signal-regulated kinase 1 and 2 (ERK1/2) expression and correlated with outcome. The primary endpoint was progression-free rate (PFR) at 3 months. RESULTS: From May 2012 to May 2013, 28 patients were enrolled at eight centers. PFR at 3 and 6 months was 44% and 20%, respectively, with 12 patients being free of progression at 3 months. Median progression-free survival (PFS) was 1.85 months (95% confidence interval [CI] 0.73-2.97) and median overall survival (OS) was 9.2 months (95% CI 5.8-12.5). No responses were observed. The most common grade 3-4 hematologic toxicities were neutropenia (48%) and leukopenia (41%) and the most frequent grade 3 non-hematologic toxicities were infection (18.5%), transaminitis (15%), fatigue (11%), and pneumonitis (11%). ERK1/2 expression was significantly correlated with PFS (p = 0.026). CONCLUSIONS: The combination of gemcitabine and sirolimus is an active treatment in STS. Further investigation is warranted. ClinicalTrials.gov identifier: NCT01684449.
BACKGROUND:Gemcitabine plus sirolimus enhances apoptosis in vitro and increases anti-tumor efficacy in vivo in soft-tissue sarcoma (STS) models. OBJECTIVE: The objective of this study was to evaluate the activity and toxicity of the combination of gemcitabine plus sirolimus in patients with STS after failure of standard chemotherapy. PATIENTS AND METHODS: Advanced STS patients, previously treated with doxorubicin and/or ifosfamide, were included in this single-arm phase II study. Patients received gemcitabine 800 mg/m2 intravenously (iv) at 10 mg/m2/min on days 1 and 8 every 3 weeks plus sirolimus 5 mg daily orally (po). After enrolment of the first 12 patients, the study protocol was amended due to toxicity and the starting dose of sirolimus was reduced to 3 mg daily po. Archival tumor samples were analyzed for extracellular signal-regulated kinase 1 and 2 (ERK1/2) expression and correlated with outcome. The primary endpoint was progression-free rate (PFR) at 3 months. RESULTS: From May 2012 to May 2013, 28 patients were enrolled at eight centers. PFR at 3 and 6 months was 44% and 20%, respectively, with 12 patients being free of progression at 3 months. Median progression-free survival (PFS) was 1.85 months (95% confidence interval [CI] 0.73-2.97) and median overall survival (OS) was 9.2 months (95% CI 5.8-12.5). No responses were observed. The most common grade 3-4 hematologic toxicities were neutropenia (48%) and leukopenia (41%) and the most frequent grade 3 non-hematologic toxicities were infection (18.5%), transaminitis (15%), fatigue (11%), and pneumonitis (11%). ERK1/2 expression was significantly correlated with PFS (p = 0.026). CONCLUSIONS: The combination of gemcitabine and sirolimus is an active treatment in STS. Further investigation is warranted. ClinicalTrials.gov identifier: NCT01684449.
Authors: M Van Glabbeke; A T van Oosterom; J W Oosterhuis; H Mouridsen; D Crowther; R Somers; J Verweij; A Santoro; J Buesa; T Tursz Journal: J Clin Oncol Date: 1999-01 Impact factor: 44.544
Authors: Xavier García-Del-Muro; Antonio López-Pousa; Joan Maurel; Javier Martín; Javier Martínez-Trufero; Antonio Casado; Auxiliadora Gómez-España; Joaquín Fra; Josefina Cruz; Andrés Poveda; Andrés Meana; Carlos Pericay; Ricardo Cubedo; Jordi Rubió; Ana De Juan; Nuria Laínez; Juan Antonio Carrasco; Raquel de Andrés; José M Buesa Journal: J Clin Oncol Date: 2011-05-23 Impact factor: 44.544
Authors: L Svancárová; J Y Blay; I R Judson; Q G C M van Hoesel; A T van Oosterom; A le Cesne; H J Keizer; C Hermans; M van Glabbeke; J Verweij; P C W Hogendoorn; O S Nielsen Journal: Eur J Cancer Date: 2002-03 Impact factor: 9.162
Authors: George D Demetri; Sant P Chawla; Isabelle Ray-Coquard; Axel Le Cesne; Arthur P Staddon; Mohammed M Milhem; Nicolas Penel; Richard F Riedel; Binh Bui-Nguyen; Lee D Cranmer; Peter Reichardt; Emmanuelle Bompas; Thierry Alcindor; Daniel Rushing; Yang Song; Ruey-Min Lee; Scot Ebbinghaus; Joseph E Eid; John W Loewy; Frank G Haluska; Pierre F Dodion; Jean-Yves Blay Journal: J Clin Oncol Date: 2013-05-28 Impact factor: 44.544
Authors: Robert G Maki; J Kyle Wathen; Shreyaskumar R Patel; Dennis A Priebat; Scott H Okuno; Brian Samuels; Michael Fanucchi; David C Harmon; Scott M Schuetze; Denise Reinke; Peter F Thall; Robert S Benjamin; Laurence H Baker; Martee L Hensley Journal: J Clin Oncol Date: 2007-07-01 Impact factor: 44.544
Authors: J T Hartmann; K Oechsle; J Huober; A Jakob; M Azemar; M Horger; L Kanz; C Bokemeyer Journal: Invest New Drugs Date: 2006-05 Impact factor: 3.651
Authors: J Martin-Liberal; M Gil-Martín; M Sáinz-Jaspeado; N Gonzalo; R Rigo; H Colom; C Muñoz; O M Tirado; X García del Muro Journal: Br J Cancer Date: 2014-07-08 Impact factor: 7.640
Authors: Matteo M Trucco; Christian F Meyer; Katherine A Thornton; Preeti Shah; Allen R Chen; Breelyn A Wilky; Maria A Carrera-Haro; Lillian C Boyer; Margaret F Ferreira; Umber Shafique; Jonathan D Powell; David M Loeb Journal: Clin Sarcoma Res Date: 2018-11-05
Authors: Paula Martínez-Delgado; Serena Lacerenza; Antonia Obrador-Hevia; Maria Lopez-Alvarez; José L Mondaza-Hernandez; Elena Blanco-Alcaina; Paloma Sanchez-Bustos; Nadia Hindi; David S Moura; Javier Martin-Broto Journal: Cells Date: 2020-06-10 Impact factor: 6.600